Dengue Fever
Dengue fever, caused by the dengue virus (DENV), is a human arboviral disease existing largely in tropical locations of the world.
Biosynth supplies peptides, biological raw materials and other products and services for pharmaceutical and life science projects.
You have successfully submitted your enquiry. Someone from our company will respond ASAP
Where chemistry meets biology, products meet services and innovation meets quality, Biosynth is at the edge of innovation. With an unrivalled research product portfolio and end-to-end manufacturing services, we are science-led and customer-focused to solve problems and deliver key reagents at scale and quality. Our expertise and capability cover complex chemicals, peptides, and key biologics.
Biosynth is an innovative supplier of reagents, custom synthesis, and manufacturing services for the life sciences industry. We are run by scientists and for scientists, securing supply chains with consistent quality worldwide. We manufacture and source a wide range of chemical and biochemical products and take pride in delivering products that others cannot.
Biosynth are experts in complex chemistry, peptides, and key biological raw materials. We provide a full range of products and services to support life science research and development, with more than half a million products in our research catalogue and hundreds of complex manufacturing service projects.
Our complex chemistry specialities include enzyme substrates, carbohydrate, and nucleoside chemistry, while our manufacturing services cover all points of the project lifespan, from route scouting to good manufacturing practice (GMP) or multi-ton-scale production. For peptides, we also have a full end-to-end offering, from lead discovery, optimisation and library production through to GMP new chemical entities (NCEs) or Neoantigen projects.
Biosynth offers an expanding range of biologically active peptides, antibodies, proteins, enzymes, and reagents for life science research. Our custom monoclonal and polyclonal antibody production complements our epitope mapping abilities, along with our key reagents for diagnostics, which include viral and bacterial antigens and antisera and plasma. Our wide array of custom and catalogue enzymes focuses on biocatalysis, allowing a synergistic project approach to both chemical and biological production of key products.
Across biologics, we have a synergistic offering, with an extensive range of custom bioprocessing enzyme projects for the production of key products. We are also able to offer custom antibody projects and epitope mapping. Through the Biosynth group, we also offer the development of antibodies, antigens, and supply of plasma for in-vitro diagnostics (IVDs).
Biosynth is a trusted supplier, manufacturer, and partner for the pharmaceutical, life science, and diagnostic sectors, serving customers across food, agrochemistry, and cosmetics. We have facilities across three continents and a rapid global distribution network.
Our main chemical research and manufacturing laboratories are in Switzerland, the UK, Slovakia, and China, with peptide production in the US and Netherlands. Our enzyme projects are based in Austria, while our biological IVD reagents are produced in Ireland. Our R&D resources and production facilities are modern and versatile, allowing us to produce chemicals on the milligram to ton scale in line with ISO 9001 and GMP standards, with peptides at mg to kg scale.
Biosynth has two manufacturing sites in Europe (Switzerland and Slovakia) for larger-scale production at ISO 9001:2015, with a flexible range of reactor sizes from 60l to 3,000l and equipped with innovative instrumentation. We also have a range of large-scale manufacturing options in Asia, including our manufacturing site in China and a flexibility service through trusted partnerships that can deliver projects of up to many tons.
Dengue fever, caused by the dengue virus (DENV), is a human arboviral disease existing largely in tropical locations of the world.
Welcome to part one of the Biosynth handbook of enzyme substrates. These important products find applications in various sectors from environmental monitoring to clinical diagnostics, from fundamental research to point-of-care devices that highly impact our health and society.
The interactions of carbohydrates with their receptors is one of the core principles that has allowed for the great diversity of cell-cell and cell-ligand recognition.
The interface between chemistry and biology becomes well and truly blurred by the cutting-edge technology of bioconjugation.
Today marks the rebranding of VIO Biosynth to Biosynth, following the company joining the Biosynth Group at the end of last year, adding a Zurich office, leading chemical R&D expertise and a global network of large-scale manufacturing partners.
We are pleased to announce that Biosynth's site in Staad, Switzerland, has successfully passed the recent GMP inspection by the US FDA on 16 January 2024.
Expansion of capacity for reliable, sustainable and flexible manufacturing solutions at any production scale.
Ready-to-Use Bioactive Products for Life Sciences Researchers Available Now